Artiva Biotherapeutics, Inc. - 10-Q Filing
Artiva Biotherapeutics reports Q3 2025 financial results including research and development expenses and updates on GC Cell license agreements.
Tickers: $ARTV
Read the full article at SEC EDGAR
Part of the story Artiva Biotherapeutics, Inc. - 10-Q Filing (3 articles)